[Pharmacokinetics and tolerability of telenzepine in patients with compensated liver cirrhosis].
Pharmacokinetics and Tolerability of Telenzepine in Patients with Chronic Liver Diseases. The pharmacokinetics and tolerability of the new selective muscarinic M1-antagonist telenzepine (BY 803; CAS 80880-90-6) were studied in 10 patients with compensated liver cirrhosis who were treated over 4 weeks with 3 mg at night. 3 mg telenzepine was well tolerated. There was no deterioration of laboratory parameters during the 4 weeks treatment course. Following a single oral dose of 3 mg telenzepine the mean maximal plasma level (cmax) averaged 5.7 (1.9-10.1) ng/ml. After repeated dosing 3 patients displayed different kinetic behaviour resulting in higher values of AUC on day 14/15 in comparison to day 1/2. tmax and cmax remained unchanged. It can be concluded that even in patients with compensated liver cirrhosis no significant accumulation of the compound will occur.
Reinicke
A
A
Krankenhaus Schwetzingen, Medizinische Universitätsklinik Heidelberg.
Müller
P
P
Dammann
H G
HG
Simon
B
B
D000293:Adolescent; D000328:Adult; D002908:Chronic Disease; D006207:Half-Life; D006801:Humans; D008103:Liver Cirrhosis / Q000378:metabolism*; D008875:Middle Aged; D010276:Parasympatholytics / Q000009:adverse effects / Q000493:pharmacokinetics*; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
D010276:Parasympatholytics; C046338:telenzepine; D010890:Pirenzepine
Pharmakokinetik und Verträglichkeit von Telenzepin bei Patienten mit kompensierter Leberzirrhose.